CoChat

Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials

Open access

The DOI matches its Crossref record; 66 of the 67 references it cites were found in a registry or an index.

Abstract

We searched Embase, PubMed, and CENTRAL from inception until 22 May 2020 to investigate which antipsychotics and/or mood stabilizers are better for patients with bipolar disorder in the maintenance phase. We performed two categorical network meta-analyses. The first included monotherapy studies and studies in which the two drugs used were specified (i.e., aripiprazole, aripiprazole once monthly, aripiprazole+lamotrigine, aripiprazole+valproate, asenapine, carbamazepine, lamotrigine, lamotrigine+valproate, lithium, lithium+oxcarbazepine, lithium+valproate, olanzapine, paliperidone, quetiapine, risperidone long-acting injection, valproate, and placebo). The second included studies on second-generation antipsychotic combination therapies (SGAs) (i.e., aripiprazole, lurasidone, olanzapine, quetiapine, and ziprasidone) with lithium or valproate (LIT/VAL) compared with placebo with LIT/VAL. Outcomes were recurrence/relapse rate of any mood episode (RR-any, primary), depressive episode (RR-dep) and manic/hypomanic/mixed episode (RR-mania), discontinuation, mortality, and individual adverse events. Risk ratios and 95% credible interval were calculated. Forty-one randomized controlled trials were identified ( n = 9821; mean study duration, 70.5 ± 36.6 weeks; percent female, 54.1%; mean age, 40.7 years). All active treatments other than carbamazepine, lamotrigine+valproate (no data) and paliperidone outperformed the placebo for RR-any. Aripiprazole+valproate, lamotrigine, lamotrigine+valproate, lithium, olanzapine, and quetiapine outperformed placebo for RR-dep. All active treatments, other than aripiprazole+valproate, carbamazepine, lamotrigine, and lamotrigine+valproate, outperformed placebo for RR-mania. Asenapine, lithium, olanzapine, quetiapine, and valproate outperformed placebo for all-cause discontinuation. All SGAs+LIT/VALs other than olanzapine+LIT/VAL outperformed placebo+LIT/VAL for RR-any. Lurasidone+LIT/VAL and quetiapine+LIT/VAL outperformed placebo+LIT/VAL for RR-dep. Aripiprazole+LIT/VAL and quetiapine+LIT/VAL outperformed placebo+LIT/VAL for RR-mania. Lurasidone+LIT/VAL and quetiapine+LIT/VAL outperformed placebo+LIT/VAL for all-cause discontinuation. Treatment efficacy, tolerability, and safety profiles differed among treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-020-00946-6

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Recurrence/relapse rate of any mood episode. Drugs were compared with placebo. To visualize heterogeneity, we used prediction intervals in the forest plot. The confidence level estimated by CINeMA is shown next to 95% PI (L: low, M: moderate, VL: very low). 95% CI: 95% credible interval, 95% PI: prediction interval, CR: confidence rating, RR: risk ratio. AOM aripiprazole once monthly, ARI aripiprazole, ASE asenapine, CAR carbamazepine, LAM lamotrigine, LIT lithium, OLA olanzapine, OXC oxcarbazepine, PAL paliperidone, QUE quetiapine, RISLAI risperidone long-acting injectable, VAL valproate.
Fig. 1 Recurrence/relapse rate of any mood episode. Drugs were compared with placebo. To visualize heterogeneity, we used prediction intervals in the forest plot. The confidence level estimated by CINeMA is shown next to 95% PI (L: low, M: moderate, VL: very low). 95% CI: 95% credible interval, 95% PI: prediction interval, CR: confidence rating, RR: risk ratio. AOM aripiprazole once monthly, ARI aripiprazole, ASE asenapine, CAR carbamazepine, LAM lamotrigine, LIT lithium, OLA olanzapine, OXC oxcarbazepine, PAL paliperidone, QUE quetiapine, RISLAI risperidone long-acting injectable, VAL valproate.CC BY · PubMed Central
Fig. 2 Recurrence/relapse rate of depressive episodes and manic/hypomanic/mixed episodes. a Recurrence/relapse rate of depressive episodes. b Recurrence/relapse rate of manic/hypomanic/mixed episodes. Drugs were compared with placebo. To visualize heterogeneity, we used prediction intervals in the forest plot. The confidence level estimated by CINeMA is shown next to 95% PI (L: low, M: moderate, VL: very low). 95% CI: 95% credible interval, 95% PI: prediction interval, CR confidence rating, RR risk ratio. AOM aripiprazole once monthly, ARI aripiprazole, ASE asenapine, CAR carbamazepine, LAM lamotrigine, LIT lithium, OLA olanzapine, OXC oxcarbazepine, PAL paliperidone, QUE quetiapine, RISLAI risperidone long-acting injectable, VAL valproate.
Fig. 2 Recurrence/relapse rate of depressive episodes and manic/hypomanic/mixed episodes. a Recurrence/relapse rate of depressive episodes. b Recurrence/relapse rate of manic/hypomanic/mixed episodes. Drugs were compared with placebo. To visualize heterogeneity, we used prediction intervals in the forest plot. The confidence level estimated by CINeMA is shown next to 95% PI (L: low, M: moderate, VL: very low). 95% CI: 95% credible interval, 95% PI: prediction interval, CR confidence rating, RR risk ratio. AOM aripiprazole once monthly, ARI aripiprazole, ASE asenapine, CAR carbamazepine, LAM lamotrigine, LIT lithium, OLA olanzapine, OXC oxcarbazepine, PAL paliperidone, QUE quetiapine, RISLAI risperidone long-acting injectable, VAL valproate.CC BY · PubMed Central
Fig. 3 All-cause discontinuation and discontinuation rate due to adverse events. a All-cause discontinuation. b Discontinuation rate due to adverse events. Drugs were compared with placebo. To visualize heterogeneity, we used prediction intervals in the forest plot. The confidence level estimated by CINeMA is shown next to 95% PI (L: low, M: moderate, VL: very low). 95% CI: 95% credible interval, 95% PI: prediction interval, CR confidence rating, RR risk ratio. AOM aripiprazole once monthly, ARI aripiprazole, ASE asenapine, CAR carbamazepine, LAM lamotrigine, LIT lithium, OLA olanzapine, OXC oxcarbazepine, PAL paliperidone, QUE quetiapine, RISLAI risperidone long-acting injectable, VAL valproate.
Fig. 3 All-cause discontinuation and discontinuation rate due to adverse events. a All-cause discontinuation. b Discontinuation rate due to adverse events. Drugs were compared with placebo. To visualize heterogeneity, we used prediction intervals in the forest plot. The confidence level estimated by CINeMA is shown next to 95% PI (L: low, M: moderate, VL: very low). 95% CI: 95% credible interval, 95% PI: prediction interval, CR confidence rating, RR risk ratio. AOM aripiprazole once monthly, ARI aripiprazole, ASE asenapine, CAR carbamazepine, LAM lamotrigine, LIT lithium, OLA olanzapine, OXC oxcarbazepine, PAL paliperidone, QUE quetiapine, RISLAI risperidone long-acting injectable, VAL valproate.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Research works printed but not linked: 1

  1. Koyama T, Higuchi T, Yamawaki S, Kanba S, Terao T, Shinohara A. Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. Jpn J Clin Psychiatry. 2011;40:369–83.

Cited by

See all 194

Metadata

Authors
Kishi, T., Ikuta, T., Matsuda, Y., Sakuma, K., Okuya, M., Mishima, K., & Iwata, N.
Affiliations
  • Fujita Health University (JP)
  • University of Mississippi (US)
  • Jikei University School of Medicine (JP)
  • Akita University (JP)
Corresponding author
Kishi, Taro
Venue
Molecular Psychiatry
Published
2020-11-11
Volume
26
Issue
8
Pages
4146-4157
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W3100071226
Cited by
169
References
67
Citations by year
2026: 20 · 2025: 33 · 2024: 35 · 2023: 41 · 2022: 31 · 2021: 8
FWCI
3.31
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Psychiatry (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • OSF Preprints (OSF Preprints) (submittedVersion)
Funders
The Health and Labor Sciences Research Grants
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
bipolar disorder, maintenance phase, mood stabilizers, antipsychotic drugs, atypical antipsychotics, lithium, valproic acid, lamotrigine, aripiprazole, olanzapine, quetiapine, asenapine, carbamazepine, paliperidone, relapse prevention, depressive episodes, manic episodes, treatment discontinuation
MeSH terms
Adult, Bipolar Disorder, Female, Humans, Antipsychotic Agents, Randomized Controlled Trials as Topic, Antimanic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1038/s41380-020-00946-6
The paper
Kishi, T., Ikuta, T., Matsuda, Y., Sakuma, K., Okuya, M., Mishima, K., & Iwata, N. (2021). Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials. Molecular Psychiatry. https://doi.org/10.1038/s41380-020-00946-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.